- Despite the announcement of positive phase III results for obeticholic acid, shares of Intercept Pharmaceuticals (ICPT) are poised for a gap down at the open.
- According to Adam Feuerstein, the product caused cardiovascular side effects in a separate phase II trial. This was disclosed in the company's recent 10-K. Intercept says the side effects are insignificant.
From other sites
at Nasdaq.com (Thu, 11:24AM)
at Zacks.com (Mar 2, 2015)
at Zacks.com (Feb 28, 2015)
at Nasdaq.com (Feb 23, 2015)
at Nasdaq.com (Jan 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs